Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease.

Taylor EN, Rimm EB, Stampfer MJ, Curhan GC.

Am Heart J. 2011 May;161(5):956-62. doi: 10.1016/j.ahj.2011.02.012.

2.

Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.

Taylor EN, Hoofnagle AN, Curhan GC.

Clin J Am Soc Nephrol. 2015 Apr 7;10(4):667-75. doi: 10.2215/CJN.07060714. Epub 2015 Jan 26.

3.

Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study.

di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S, Isermann B, Hense HW, Dierkes J, Boeing H, Stangl GI, Weikert C.

J Clin Endocrinol Metab. 2014 Mar;99(3):947-55. doi: 10.1210/jc.2013-2963. Epub 2013 Jan 1.

PMID:
24423292
4.

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M.

Kidney Int. 2011 Jun;79(12):1370-8. doi: 10.1038/ki.2011.47. Epub 2011 Mar 9. Erratum in: Kidney Int. 2012 Aug;82(4):498.

5.

Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.

Brandenburg VM, Kleber ME, Vervloet MG, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H.

Atherosclerosis. 2014 Nov;237(1):53-9. doi: 10.1016/j.atherosclerosis.2014.08.037. Epub 2014 Aug 28.

PMID:
25200615
6.

Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.

Sánchez Fructuoso AI, Maestro ML, Calvo N, De La Orden V, Pérez Flores I, Vidaurreta M, Valero R, Fernández-Pérez C, Barrientos A.

Transplant Proc. 2012 Nov;44(9):2551-4. doi: 10.1016/j.transproceed.2012.09.070.

PMID:
23146451
7.

Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.

Scialla JJ, Parekh RS, Eustace JA, Astor BC, Plantinga L, Jaar BG, Shafi T, Coresh J, Powe NR, Melamed ML.

Am J Nephrol. 2015;42(1):25-34. doi: 10.1159/000438999. Epub 2015 Aug 20.

8.

Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men.

Marsell R, Grundberg E, Krajisnik T, Mallmin H, Karlsson M, Mellström D, Orwoll E, Ohlsson C, Jonsson KB, Ljunggren O, Larsson TE.

Eur J Endocrinol. 2008 Jan;158(1):125-9. doi: 10.1530/EJE-07-0534.

9.

Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.

Sánchez Fructuoso AI, Maestro ML, Pérez-Flores I, Valero R, Rafael S, Veganzones S, Calvo N, De la Orden V, De la Flor JC, Valga F, Vidaurreta M, Fernández-Pérez C, Barrientos A.

Nephrol Dial Transplant. 2012 Nov;27(11):4227-35. doi: 10.1093/ndt/gfs409.

PMID:
23144073
10.

Abnormalities in renal tubular phosphate handling in children with sickle cell disease.

Raj VM, Freundlich M, Hamideh D, Alvarez O, Seeherunvong W, Abitbol C, Katsoufis C, Chandar J, Ruiz P, Zilleruelo G.

Pediatr Blood Cancer. 2014 Dec;61(12):2267-70. doi: 10.1002/pbc.25188. Epub 2014 Aug 17.

PMID:
25132581
11.

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.

Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M.

Kidney Int. 2006 Feb;69(3):531-7.

12.

Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.

Gutiérrez OM, Wolf M, Taylor EN.

Clin J Am Soc Nephrol. 2011 Dec;6(12):2871-8. doi: 10.2215/CJN.02740311. Epub 2011 Oct 27.

13.

Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease.

Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A.

Clin J Am Soc Nephrol. 2010 Oct;5(10):1780-6. doi: 10.2215/CJN.02560310. Epub 2010 Jun 24.

14.

The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.

Taal MW, Thurston V, McIntyre NJ, Fluck RJ, McIntyre CW.

Kidney Int. 2014 Aug;86(2):407-13. doi: 10.1038/ki.2013.537. Epub 2014 Jan 15.

PMID:
24429404
15.
16.

Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study.

Kamycheva E, Sundsfjord J, Jorde R.

Eur J Cardiovasc Prev Rehabil. 2004 Feb;11(1):69-74.

PMID:
15167209
17.

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.

Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Okada N, Tsubakihara Y, Rakugi H, Isaka Y.

Bone. 2012 Jun;50(6):1266-74. doi: 10.1016/j.bone.2012.02.634. Epub 2012 Mar 6.

PMID:
22425694
18.

Phosphate homeostasis, parathyroid hormone, and fibroblast growth factor 23 in stages 3 and 4 chronic kidney disease.

Phelps KR, Mason DL, Stote KS.

Clin Nephrol. 2016 May;85(5):251-61. doi: 10.5414/CN108686.

PMID:
26951967
19.

Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study.

di Giuseppe R, Kühn T, Hirche F, Buijsse B, Dierkes J, Fritsche A, Kaaks R, Boeing H, Stangl GI, Weikert C.

PLoS One. 2015 Jul 20;10(7):e0133580. doi: 10.1371/journal.pone.0133580. eCollection 2015.

20.

Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.

Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM.

JAMA. 2002 Aug 28;288(8):980-7.

PMID:
12190368

Supplemental Content

Support Center